NCT03841097View on ClinicalTrials.gov

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 11, 2019

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Kidney Transplant; Complications
Interventions
DRUG

Extended Release Tacrolimus Tablets

The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.

DRUG

Immediate Release Tacrolimus Capsule

The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.

Trial Locations (1)

19104

Hospital of the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals
All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Roy D. Bloom, MD

OTHER